Physician profile
Shannon Malone
NPI 1659586113
$2,003.68
in general payments reported to CMS, 2019-2025
26 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $181 · 2021: $277 · 2022: $466 · 2023: $185 · 2024: $478 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.89 | 2019-2025 | |
| Novo Nordisk INC | $272.58 | 2022-2025 | Wegovy |
| Biogen, INC. | $200.19 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $127.63 | 2022-2025 | |
| Pfizer INC. | $117.87 | 2022-2025 | |
| Avion Pharmaceuticals | $79.88 | 2021-2023 | Balcoltra |
| Mylan Pharmaceuticals INC. | $74.65 | 2019-2022 | |
| Lupin INC. | $73.77 | 2019-2021 | |
| Exeltis, USA INC. | $68.05 | 2024-2025 | Slynd |
| Channel Medsystems, INC. | $54.65 | 2022-2023 | |
| Hologic Sales and Service, LLC | $39.77 | 2022 | |
| Coopersurgical, INC. | $32.31 | 2020-2024 | Paragard T 380a |
| Astellas Pharma US INC | $30.54 | 2024 | Veozah |
| Evofem Biosciences, INC. | $29.71 | 2020-2022 | |
| Myovant Sciences INC. | $26.31 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.52 | 2024 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $24.24 | 2024 | Exparel |
| Duchesnay USA Incorporated | $21.43 | 2019 | |
| Optumhealth Care Solutions, LLC | $21.43 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Shield Therapeutics INC | $20.85 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.59 | 2021 | |
| Convatec INC. | $18.90 | 2019 | |
| Virtus Pharmaceuticals LLC | $16.98 | 2021 | |
| Davol INC. | $16.76 | 2024 | Arista Ah Flexitip |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2020 | |
| Therapeuticsmd, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.